Prior to joining Endeavor Biomedicines, Dr. Pendyala was leading the clinical development at BridgeBio focusing on rare diseases. He is a physician-scientist with over 20 years of experience in clinical research, translational sciences and academic medicine. He has a strong background in inflammation, immunology and oncology therapeutic areas. Prior to BridgeBio, he was at Theravance, Merck, Roche/Genentech and led the development of a number of molecules from early/late-stage clinical trials to regulatory approval. He was involved in multiple NDA filings with approvals and in partnered drug development programs. He has a passion for developing new medicines that make a difference in patients’ lives.